250 related articles for article (PubMed ID: 10998193)
1. The cannabinoid system and cytokine network.
Klein TW; Lane B; Newton CA; Friedman H
Proc Soc Exp Biol Med; 2000 Oct; 225(1):1-8. PubMed ID: 10998193
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptors and their endogenous agonist, anandamide.
Axelrod J; Felder CC
Neurochem Res; 1998 May; 23(5):575-81. PubMed ID: 9566594
[TBL] [Abstract][Full Text] [Related]
3. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
4. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
5. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
6. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
Di Marzo V; Bisogno T; De Petrocellis L; Melck D; Martin BR
Curr Med Chem; 1999 Aug; 6(8):721-44. PubMed ID: 10469888
[TBL] [Abstract][Full Text] [Related]
7. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.
Bisogno T; Melck D; Bobrov MYu ; Gretskaya NM; Bezuglov VV; De Petrocellis L; Di Marzo V
Biochem J; 2000 Nov; 351 Pt 3(Pt 3):817-24. PubMed ID: 11042139
[TBL] [Abstract][Full Text] [Related]
8. Biochemistry of the endogenous ligands of cannabinoid receptors.
Di Marzo V; Deutsch DG
Neurobiol Dis; 1998 Dec; 5(6 Pt B):386-404. PubMed ID: 9974173
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats.
Wiley JL; Ryan WJ; Razdan RK; Martin BR
Eur J Pharmacol; 1998 Aug; 355(2-3):113-8. PubMed ID: 9760024
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.
Hegde VL; Hegde S; Cravatt BF; Hofseth LJ; Nagarkatti M; Nagarkatti PS
Mol Pharmacol; 2008 Jul; 74(1):20-33. PubMed ID: 18388242
[TBL] [Abstract][Full Text] [Related]
11. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.
De Petrocellis L; Melck D; Palmisano A; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8375-80. PubMed ID: 9653194
[TBL] [Abstract][Full Text] [Related]
12. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation.
Do Y; McKallip RJ; Nagarkatti M; Nagarkatti PS
J Immunol; 2004 Aug; 173(4):2373-82. PubMed ID: 15294950
[TBL] [Abstract][Full Text] [Related]
13. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells.
Lau AH; Chow SS
Eur J Pharmacol; 2003 Mar; 464(2-3):229-35. PubMed ID: 12620517
[TBL] [Abstract][Full Text] [Related]
14. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids in the central nervous system--an overview.
Fride E
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):221-33. PubMed ID: 12052038
[TBL] [Abstract][Full Text] [Related]
16. Anandamide, a natural ligand for the peripheral cannabinoid receptor is a novel synergistic growth factor for hematopoietic cells.
Valk P; Verbakel S; Vankan Y; Hol S; Mancham S; Ploemacher R; Mayen A; Löwenberg B; Delwel R
Blood; 1997 Aug; 90(4):1448-57. PubMed ID: 9269762
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoid ligand-receptor signaling in the mouse uterus.
Das SK; Paria BC; Chakraborty I; Dey SK
Proc Natl Acad Sci U S A; 1995 May; 92(10):4332-6. PubMed ID: 7753807
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.
Farquhar-Smith WP; Jaggar SI; Rice AS
Pain; 2002 May; 97(1-2):11-21. PubMed ID: 12031775
[TBL] [Abstract][Full Text] [Related]
19. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
20. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
Molina-Holgado F; Molina-Holgado E; Guaza C; Rothwell NJ
J Neurosci Res; 2002 Mar; 67(6):829-36. PubMed ID: 11891798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
